Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Hoofdauteurs: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
Elsevier
2019
|
Gelijkaardige items
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
door: Theodora Markati, et al.
Gepubliceerd in: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
door: Marshall W. Hogarth, et al.
Gepubliceerd in: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
door: Fatima Amor, et al.
Gepubliceerd in: (2021-06-01) -
Duchenne Muscular Dystrophy
door: J Gordon Millichap
Gepubliceerd in: (1989-05-01) -
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
door: Frank, DE, et al.
Gepubliceerd in: (2020)